NF1 Brain Tumor Genetic Risk
This study will analyze DNA samples to determine associations between maternal and offspring genetic factors and pediatric brain tumor development in children with Neurofibromatosis Type 1. Participating families (mother, father, child) will be asked to complete a short questionnaire and provide DNA samples (either saliva or blood). The information gained from your participation may one day help doctors develop strategies to reduce brain tumor risk in individuals with NF1. Please note: there is no therapy associated with this study.
Neurofibromatosis Type 1
Pediatric Brain Tumor
|Study Design:||Observational Model: Family-Based
Time Perspective: Cross-Sectional
|Official Title:||Genetic Variation and Risk of Pediatric Brain Cancers|
- Brain Tumor [ Time Frame: September 1, 2012-February 1, 2014 ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Blood or saliva samples
|Study Start Date:||October 2012|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Families with a child with Neurofibromatosis Type 1 who has been diagnosed with a brain tumor.
The prenatal period is a developmentally vulnerable time point during which environmental conditions, including nutrition, can have life-long impacts on health.1,2 This is particularly relevant to many childhood cancers that are thought to initiate during pregnancy.3 As a consequence, there has been intense interest in whether prenatal exposures can modulate childhood cancer risk.4-6 It is important to recognize that both maternal and offspring genetic factors including those in nutritional pathways may play an important role in pediatric cancer risk through their effect on the child's exposure to nutrients important in development during the prenatal period. The purpose of this research study is to evaluate whether there are any maternal or offspring genetic factors in the folate pathway that may contribute to the development of brain tumors in children with Neurofibromatosis Type 1 through analysis of DNA samples collected from families.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01707836
|United States, Missouri|
|St. Louis, Missouri, United States, 63130|
|Principal Investigator:||Kimberly J Johnson, PhD||Washington University School of Medicine|